U.S FDA strengthens warnings on Glaxo, Roche/Biogen cancer drugs
Sept 25 (Reuters) - U.S. regulators strengthened the warning labels on two cancer drugs - GlaxoSmithKline Plc's Arzerra, and Rituxan, made by Biogen Idec Inc and Roche Holding AG - to reflect the risk that they can reactivate the hepatitis B virus in patients previously infected with it.
The U.S. Food and Drug Administration said the risk is already described in the warnings and precautions section of the label for both drugs. Now the information will be placed in a black box, indicating the most serious type of risk.
- U.S. air strikes on Syria would face formidable obstacles
- Samsung unveils smartwatch that can make calls
- FBI, Secret Service investigate reports of cyber attacks on U.S. banks
- Breakthrough hopes dented as Ukraine accuses Russia of new incursion |
- Russian-backed separatists enter southeast Ukraine town